A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
The reason for this study is to see if the study drug mirikizumab is safe and effective in participants with moderately to severely active Crohn's disease.
The study will last about 72 weeks and may include up to 19 visits.
Key Participation Requirements
All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria
-Participants must have a diagnosis of Crohn's Disease (CD) for at least 3 months prior to baseline
-Participants must have a confirmed diagnosis of moderate to severe CD
-Participants must have demonstrated intolerance, loss of response or inadequate response to conventional or to biologic therapy for CD
-Participants must, if female, meet the contraception recommendations
-Participants must not have a current diagnosis of ulcerative colitis, inflammatory bowel disease-unclassified (IBD-U) (formerly known as indeterminate colitis), abdominal or perianal abscess or short bowel syndrome
-Participants must not have a stoma or ostomy
-Participants must not have had a bowel resection within 6 months, or any kind of intra-abdominal or extra abdominal surgery within 3 months of baseline
-Participants must not have ever received any monoclonal antibodies binding IL-23